BCS & IVIVC Based Biowaivers
In the era of swelling costs of drug development and shrinking budgets, the pharmaceutical industry has been striving hard to find ways for saving precious resources. Tools evolved through naive scientific probing, like BCS (Biopharmaceutics Classification System) and IVIVC (invitro and invivo classification) can act as the magic-wands in such cases. Besides obtaining biowaivers, IVIVC has been applied in drug delivery during various stages of development, like formulation screening, setting dissolution specifications and product development. Nonetheless, the most critical pharmaco-economic application is the biowaiver by avoidance of expensive clinical trials. Newer paradigms like in vitro/in vivo relationship (IVIVR) are also being deliberated and practiced at industrial level, esp. for IR formulations.
- BCS biowaivers
- Preclinical and clinical testing for oral drug delivery
- Waiver for In vivo bioavailability or bioequivalence
- Consideration of biowaiver extensions for BCS class III drugs
- In vitro diffusion cells for dissolution testing in formulation development
- Dissolution testing in drug formulation
- In vitro preclinical ADME/BCS testing
- In vitro drug product research
- Biowaiver approval for Biosimilars
Related Conference of BCS & IVIVC Based Biowaivers
BCS & IVIVC Based Biowaivers Conference Speakers
Recommended Sessions
- BCS & IVIVC Based Biowaivers
- Bioequivalence Assessment
- Biosimilar Companies and Market Analysis
- Biosimilar Market and Cost Analysis
- Biosimilars Analytical Strategies
- Biosimilars Research Pipeline
- Brexit Effect on Biosimilars
- Challenges in Developing Biosimilars
- Clinical Studies on Biosimilars
- Emerging Biosimilars in Therapeutics
- Emerging Trends in Biosimilars
- Entrepreneurs Investment Meet
- Globalization of Biosimilars
- Intellectual Property Rights
- Latest Biosimilars in Asian Scenario
- Legal Issues and BPCI Act
- Pharmacovigilance of Biosimilars
- Regulatory Approach for Biosimilars